PDCD1 and hepatocellular carcinoma: Therefore, this meta-analysis aims to consolidate the current evidence regarding the efficacy of combining HAIC, lenvatinib, and PD-1 inhibitors for the treatment of unresectable hepatocellular carcinoma.